On June 30, Abivax S.A. rose 36.68% in regular trading, trading at $131.05/share, with turnover of $194 million.

The rally was driven by positive supplemental Phase 3 maintenance trial results for its lead drug obefazimod in ulcerative colitis. ABTECT Maintenance Part 2 data showed that among induction non-responders, 50mg obefazimod achieved 37.2% clinical remission and 61.5% clinical response at Week 44. Among patients who relapsed during Part 1, re-treatment achieved 69.7% response and 45.0% remission rates. Critically, no new safety signals emerged, with malignancy rates remaining consistent with expected background rates.

This data directly addresses prior safety concerns that had caused the stock to plunge nearly 50% from approximately $130 to $70 after multiple cancer cases were reported in the 50mg group. Wedbush raised its price target from $90 to $110 while maintaining a Neutral rating. The analyst consensus target stands at $148.17. The company confirmed plans to submit a New Drug Application to the FDA in Q4.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)